Trial site
Maryland Oncology Hematology P.A.
Silver Spring, Maryland 20904, United StatesNot linked to an institution yet
- 12running trials
- 1closed trial
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Phase 21 trial
- Status
- Active, not recruiting6 trials
- Recruiting5 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Pfizer4 trials
- Janssen Research & Development, LLC3 trials
- US Oncology Research2 trials
- Astellas Pharma Global Development, Inc.1 trial
- Daiichi Sankyo1 trial
- and 2 more
Running trials
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892· Phase 2/3· Pfizer· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831· Phase 2/3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
MYLUNG Consortium Part 3: Observational Study
NCT05885698· US Oncology Research· Source
Contact: Andrea Glidden, BSN, OCN
Active, not recruiting
MYLUNG Consortium Study Protocol 2
NCT05644808· US Oncology Research· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error